by [email protected] | May 10, 2019 | Endocrine
Abstract Authors: Levin P, Wei W, Miao R, Ye F, Xie L, Baser O, Gill J Aims: To evaluate real-world clinical outcomes for switching basal insulin analogues [insulin glargine (GLA) and insulin detemir (DET)] among US patients with type 2 diabetes mellitus (T2DM)....
by [email protected] | May 9, 2019 | Endocrine, Publication
Abstract Authors: Wei W, Zhou S, Miao R, Pan C, Xie L, Baser O, Gill J. Introduction: Type-2 diabetes mellitus (T2DM) is a progressive disease, and many patients eventually require insulin therapy. This study examined real-world outcomes of switching basal...
by [email protected] | May 8, 2019 | Endocrine, Publication
ABSTRACT Authors: Levin P, Lin J, Wei W, Vlajnic A, Pan C, Xie L, Baser O. Objective: To examine treatment patterns and outcomes of initiation of injectable pen therapy with either insulin glargine or liraglutide, and to evaluate comparative effectiveness. Study...
by [email protected] | May 7, 2019 | Endocrine
Abstract Authors: Xie L, Zhou S, Pinsky BW, Buysman EK, Baser O. Background: Diabetes accounts for almost 15% of all direct healthcare expenditures. Managed care organizations try to reduce costs and improve patient outcomes. Increasing patient persistence with...
by [email protected] | May 6, 2019 | Endocrine
Abstract Authors: Levin PA, Wei W, Zhou S, Xie L, Baser O. Background: Patients with uncontrolled type 2 diabetes mellitus (T2DM), despite therapy with 2 oral antidiabetic drugs (OADs), may add a third OAD or a glucagon-like peptide-1 receptor agonist (GLP-1) or...
by [email protected] | May 5, 2019 | Endocrine, Publication
Abstract Authors: Miao R, Wei W, Lin J, Xie L, Baser O. We compared real-world clinical and economic outcomes for insulin glargine treatment administered by disposable pen and traditional vial-and-syringe injections among elderly patients with type 2 diabetes mellitus...
